sugar chain antigen 19-9

The carbohydrate antigen CAl9-9 (CAl9-9) is an oligosaccharide-like tumor-associated carbohydrate antigen with a molecular weight greater than 5000 kD. CAl9-9 is a sialylated Lewisa antigen characterized by either a ganglioside in the cell membrane or a glycoprotein formed by fluid mucus, and the sialic acid in the blood is present as a mucin glycoprotein. CAl9-9 is a tumor marker for colorectal cancer and pancreatic cancer. Basic Information Specialist classification: Oncology examination classification: biochemical examination Applicable gender: whether men and women apply fasting: fasting Tips: After the incubation, the process of washing the reaction tube should be consistent. Normal value (8.4 ± 7.4) kU / L. Clinical significance 1. The level of serum CAl9-9 in patients with liver cancer is often significantly increased. The level of CAl9-9 is positively correlated with clinical stage, mass size and lymph node metastasis. After surgery, CAl9-9 decreased significantly and increased again after recurrence. Dynamic observation of changes in the content of CAl9-9 has certain clinical significance for the monitoring of disease, efficacy evaluation and prognosis of liver cancer patients. 2, serum levels of CAl9-9 can also be found in pancreatic cancer, gastric cancer, lung cancer, colorectal cancer and ovarian cancer and other malignant tumors, and serum CA242 detection is helpful for the disease monitoring, efficacy evaluation and prognosis of the above tumors. 3, non-neoplastic diseases such as chronic pancreatitis, cholelithiasis, cirrhosis, renal insufficiency and diabetes can also increase the increase of CAl9-9, but mostly low concentration or transient increase. Detection of serum CAI9-9 is helpful for the differential diagnosis of benign and malignant diseases of the digestive tract (such as pancreatic cancer and pancreatitis, gastric cancer and gastric ulcer). High results may be diseases: pancreatic cancer, rectal cancer, colorectal cancer, malignant tumors 1. Digestive tract adenocarcinoma, especially pancreatic and biliary system malignant tumors: positive rate >80%, is an important auxiliary diagnostic index, which is of great value for monitoring disease changes and recurrence. 2. The method has a measurement range of 10 to 300 u/ml, and a sample with a CA-19-9 content of more than 300 u/ml can be determined by appropriately diluting the dilution provided by the kit. The content of the sample CA-19-9 is the measured value multiplied by the dilution factor. 3. After the incubation, the process steps of the washing reaction tube are consistent. Inspection process All reagents and samples to be tested should be equilibrated at room temperature (18 ~ 25 ° C), and thoroughly mixed before loading. The CA-19-9 coated reaction tube number is standard, the quality control serum and the sample should be duplicated, and the 1 and 2 tubes are the total radioactivity (T) tube can be replaced by the polyethylene tube not coated with CA-19-9. . 1. Add standard/test sample and 125ICA-19-9B25, 10 monoclonal antibody in sequence. 2. All reaction tubes (except T tube) were placed in a vortex mixer (250r/min) for 60±10s, then the upper part of the reaction tube was covered with a plastic film, and incubated at 37°C in a water bath for 3 hours. 3. After aspirating the liquid in the reaction tube, the reaction tube is washed twice with 2 ml of water, and the liquid must be discarded after each washing. 4. Measure the radioactivity count of all reaction tubes and take the average value of each pair of tubes (including T tube). Not suitable for the crowd Those without indications should not be tested. Adverse reactions and risks 1. Infection: Pay attention to aseptic operation when collecting blood, avoid contamination of water and other parts at the blood collection site to avoid local infection. 2, bleeding: after the blood is given a full compression time, especially coagulopathy, bleeding tendency, to avoid local subcutaneous oozing, bruising and swelling.